FDA Nod For Breast Cancer Combo Therapy, RARE Scripts History, EDAP Disappoints

Today's Daily Dose brings you news about FDA approval of Faslodex-Verzenio combo for advanced breast cancer; EDAP's disappointing Q3 results; upcoming clinical trial catalysts of TapImmune, and the first drug to be greenlighted for Sly syndrome.

from RTT - Biotech http://ift.tt/2AOxeKm
via IFTTT